CG Oncology (CGON) Equity Ratio (2023 - 2026)

CG Oncology has reported Equity Ratio for 4 years, with the latest figure at 0.96 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 0.63% year-over-year to 0.96; the trailing twelve-month figure through Mar 2026 stood at 0.96 (down 0.63% YoY), and the FY2025 full-year result was 0.95, down 2.15% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.96, up from 0.95 in the prior quarter.
• The five-year high for Equity Ratio was 0.98 in Q1 2024, with the low at 0.62 in Q4 2023.
• Historically, Equity Ratio has averaged 0.81 across 4 years, with a median of 0.96 in 2025.
• Annual changes were most pronounced in 2024 — Equity Ratio soared 257.31% — and 2025, when it decreased 3.04%.
• CG Oncology's Equity Ratio stood at 0.62 in 2023, then soared by 257.31% to 0.97 in 2024, then slipped by 2.15% to 0.95 in 2025, then grew by 1.15% to 0.96 in 2026.
• The last three Equity Ratio figures came in at 0.96 (Q1 2026), 0.95 (Q4 2025), and 0.94 (Q3 2025), per Business Quant data.